Biotech Firm Omega Therapeutics OK'd For $14M Ch. 11 Sale
By Clara Geoghegan · April 23, 2025, 5:18 PM EDT
Biotechnology developer Omega Therapeutics received a Delaware bankruptcy judge's approval Wednesday to sell itself to its debtor-in-possession lender and a major shareholder for $14 million in Chapter 11....
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login